Mechanism of action behind novel cancer agents targeting tumor cell metabolism discovered
Tuesday, July 26, 2011 - 04:00
in Health & Medicine
(Medical Xpress) -- The discovery of the mechanism of action behind a novel class of anticancer drugs designed to disrupt cancer cell mitochondrial metabolism may be a major step toward furthering clinical trials of the agents. An analysis of CPI-613, the lead compound in this first-in-class group of anticancer drugs developed by Paul M. Bingham, Ph.D., Associate Professor, and Zuzana Zachar, Ph.D., Research Assistant Professor, both in the Department of Biochemistry and Cell Biology, Stony Brook University School of Medicine, is published in the Journal of Molecular Medicine.